Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
- Issued Date
- 2020
- Type
- Article
- Publisher
- MOLECULAR CANCER THERAPEUTICS
- Language
- 영어
- ISSN
- 1535-7163
- Citation Volume
- 19
- Citation Number
- 5
- Citation Start Page
- 1210
- Citation End Page
- 1217
- 파일 목록
-
-
관련 파일이 존재하지 않습니다.
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.